Natera opened lower at $425.55, compared with its previous close of $436.00. In the last trading session, the stock traded between $412.57 and $431.26. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Natera is now worth
$ 360.69
giving a profit of
$ 260.69 (260.69%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 20 Analysts
Buy
95%
Hold
5%
Sell
0%
Markets Today
Today's Change
$-22.76 (-5.22%)
Day High
$431.26
Day Low
$412.57
Day Open
$425.55
Prev Close
$436.00
Volume
7,72,737
1W Return
2.89%
1M Return
-0.32%
3M Return
62.71%
6M Return
112.19%
1Y Return
114.32%
Fundamentals
Market Cap ($ Mn)
59,566
PE Ratio
-
PB Ratio
25.72
PEG Ratio
-
ROE
-15.66%
ROCE
-20.96%
EPS (TTM)
$-0.47
Investment Returns
1 Week
2.89%
1 Month
-0.32%
3 Months
62.71%
6 Months
112.19%
9 Months
78.52%
Financials
Quarterly
All values in $ Mn
476.1
Dec 24
501.8
Mar 25
546.6
Jun 25
592.2
Sep 25
665.5
Dec 25
752.8
Jun 26
Updates
22Oct
Natera stock: $100 investment grows to $356 in five years
Natera shares delivered an average annual return of 28.94% over five years. The stock outperformed the market by 17.81% on an annualized basis. A $100 investment made five years ago is now worth $356.36. Current market capitalization stands at $57.57 billion.
8 days ago
19Oct
Natera to present 20 abstracts at ESMO 2026 on MRD tech
Natera to present 20 abstracts at ESMO 2026 in Madrid. Signatera Genome detects ctDNA below 1 part per 10 million. SAGITTARIUS trial: Treatment changed for 1 in 3 colon cancer patients. 87% of influenced changes involved treatment de-escalation.
11 days ago
15Oct
Natera’s Signatera test named to TIME’s best inventions list for 2026
Natera’s Signatera MRD test named to TIME’s Best Inventions of 2026 list. Test detects circulating tumor DNA up to two years before imaging shows recurrence. Used by more than 55% of oncologists in the United States. Supported by over 200 peer-reviewed publications. Natera also named to Fortune’s Future 120 list for innovation.
15 days ago
7Oct
Citigroup raises Natera price target to $480, maintains Buy rating
Citigroup raises Natera price target from $365 to $480. Albert Hu maintains Buy rating on the stock. Guggenheim previously raised target from $360 to $475. Both firms increased targets by exactly $115 per share.
23 days ago
5Oct
Natera, Alliance launch Phase III trial for early breast cancer
Natera and Alliance Foundation Trials launched AFT-70 NAVIGATE, a Phase III trial. The study uses Signatera MRD test to guide treatment in early breast cancer. Trial aims to reduce unnecessary CDK4/6 inhibitor exposure and toxicities. Collaboration includes co-funding from Natera and Genentech.
Average annual return of 29.65% over five years. Outperformed the market by 17.64% on an annualized basis. $1,000 investment grew to $3,694.99 at current price of $411.77. Current market capitalization stands at $59.35 billion.
